Thrombosis

touchCARDIO spoke with Dr Ganesan Karthikeyan All India Institute of Medical Sciences (AIIMS), New Delhi, India to get the results from the SAFE-PVT trial, presented at ESC 2024. SAFE-PVT was created to look at the difference in outcomes between surgery and fibrinolytic therapy to treat left-sided mechanical valve thrombosis, a condition that, while rare in developed countries, continues to affect patients in low- and middle-income countries where there are additional challenges in maintaining anticoagulation. This study looked to discern the differences in outcomes between surgery, the most common option in developed countries and also most recommended in Western guidelines, and fibrinolytic therapy with a low-dose, slow-infusion tPA regimen.

The COVID-PACT study focused on critically ill patients with coronavirus disease 2019 (COVID-19), assessing the use of antithrombotic therapy. In this touchCARDIO interview, we speak with Dr David Berg (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA) to discuss the purpose and design of the COVID-19 study and how the outcomes will implicate […]

Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2). Increased risk of thrombotic events is seen in patients infected with SARS-CoV-2, which is higher in patients needing critical care. In this touchCARDIO interview, we speak with Dr David Berg (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, […]